Processa Pharmaceuticals
Hanover based Biotechnology firm.
Launch date
Employees
Market cap
$4.4m
Enterprise valuation
($1m) (Public information from Sep 2024)
Share price
$1.37 PCSA
Hanover Pennsylvania (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | - | - | - | - | - | - | 40.0m |
EBITDA | (5.6m) | (10.8m) | (12.2m) | (11.5m) | - | - | - |
Profit | (14.4m) | (11.4m) | (27.4m) | (11.1m) | (11.9m) | (13.0m) | (14.6m) |
% profit margin | - | - | - | - | - | - | (37 %) |
EV / revenue | - | - | - | - | - | - | 0.1x |
EV / EBITDA | -12.4x | -7.2x | -1.4x | -0.7x | - | - | - |
R&D budget | 3.2m | 6.9m | 11.5m | 5.8m | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | $1.5m | Early VC | |
N/A | N/A | IPO | |
N/A | $2.5m | Post IPO Equity | |
* | N/A | $7.0m | Post IPO Equity |
Total Funding | $1.5m |
Related Content
Recent News about Processa Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.